ReviewInfectious diseases and therapy2022
Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China.
Review in Infectious diseases and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- [Analysis of epidemiological characteristics and spatial clustering of hepatitis C virus in China from 2018 to 2022].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Economic evaluation of alternative hepatitis C treatment options: a post hoc analysis of the VIETNARMS trial.EClinicalMedicine · 2026Article
- [Care regulation and regional governance in viral hepatitis microelimination strategies].Cadernos de saude publica · 2026Article
- Pathway to hepatitis C elimination: insights from a large tertiary hospital in South China.Annals of medicine · 2025Article
- Community-based versus facility-based services to improve hepatitis C screening in Cambodia: a cluster randomized controlled trial (ANRS 12384 Cam-C study).The Lancet regional health. Western Pacific · 2025Article
- Virtual screening, optimization design, and synthesis analysis of novel benzofuran derivatives as pan-genotypic HCV NS5B polymerase inhibitors using molecular modeling.BMC chemistry · 2025Article
- Age-period-cohort and bayesian age-period-cohort prediction modeling of hepatitis C incidence and mortality in China.BMC public health · 2025Article
- The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China.BMC public health · 2025Article
- Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.Clinical and molecular hepatology · 2025Article
- [Analysis of the results of the Fuxing Program Action for micro-elimination of hepatitis C in Zhuhai].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Assessing the knowledge, attitudes, and psychological health of people who use drugs towards Hepatitis C: a cross-sectional study.Frontiers in public health · 2025Article
- Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.Infectious diseases and therapy · 2025Article
- Awareness of hepatitis C prevention and treatment and high-risk behaviors among the general population in Anhui Province: a cross-sectional study.Frontiers in public health · 2025Article
- Review
- Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.PharmacoEconomics · 2024Article
- HCV RNA positivity among hepatitis C patients in Chongqing, China from 2004 to 2021: a cross-sectional study.BMC infectious diseases · 2024Article
- Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis.JHEP reports : innovation in hepatology · 2024Article
- Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?Cost effectiveness and resource allocation : C/E · 2024Article
- Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021.Infectious diseases of poverty · 2023Article
- Global Epidemiology of Hepatocellular Carcinoma.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionAs a country that is heavily burdened by hepatitis C, China's successful responses to this public health threat have significant implications for the achievement of the global elimination goal.
methodsThis article reviews China's strategies for prevention, screening, diagnosis, access to direct-acting antiviral agents (DAA) therapy, and patient management of hepatitis C. It also analyses the major challenges and summarizes the valuable successful international experiences that have implications for China to achieve the elimination goal.
resultsTo promote the achievement of elimination, China has taken a series of proactive measures to promote the prevention and treatment of hepatitis C. Compared with other middle-income countries, there is still much room for China to achieve universal screening, diagnosis and treatment based on a streamlined disease management procedure. A stronger role of primary care in an integrated healthcare delivery system and integration of hepatitis C with other infectious disease programs should also be the focus of China's efforts.
conclusionsAs a developing country with a large population, a "micro-elimination" strategy with focused screening and proactive diagnosis and treatment for the vulnerable population may be a more practical approach to eliminating hepatitis C in China. Continued efforts are needed to fully overcome the intellectual property barriers of sofosbuvir for forming the more competitive pan-genotype DAA combinations based on the locally developed DAAs. Meanwhile, the safety net for patients in economic hardship needs to be further strengthened. More importantly, it is necessary to promote patients' willingness and compliance with standard treatment through increased awareness of hepatitis C. The development of an integrated healthcare delivery system, a disease management procedure which is suitable for primary care, and full compliance of the primary care providers are also important to achieve effective cascade care management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.